Skip to main content

Immucell Value Stock - Dividend - Research Selection

Immucell

ISIN: US4525253062 , WKN: 885825

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

2026-02-18
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ETPORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a conference cal

Niche Focus & Regulation Shape the Future of Healthcare Firms

2026-01-15
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.

Those who invested in ImmuCell (NASDAQ:ICCC) a year ago are up 25%

2026-01-12
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

ImmuCell Q4 Earnings Call Highlights

2026-01-09
ImmuCell (NASDAQ:ICCC) used a January 9 conference call to outline a strategic shift toward its First Defense calf-health franchise while reporting unaudited fourth-quarter and full-year 2025 sales results. Management said the company will pause investment in Re-Tain, its long-developed mastitis tre

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

2026-01-09
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call January 9, 2026 9:00 AM ESTCompany ParticipantsP. F.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

2026-01-08
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Compan

ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024

2026-01-08
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary,

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

2026-01-07
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ETPORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and

ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business

2025-12-29
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an

ImmuCell Puts Re-Tain On Pause After FDA Letter

2025-12-26
Animal health company ImmuCell receives an Incomplete Letter from the FDA for its Re-Tain NADA. Company shifts focus to First Defense.